Lescol (fluvastatin sodium)

Company: Novartis
Approval Status: Approved September 1997
Treatment for: coronary atherosclerosis
Areas: Cardiovascular / Cardiology; Diabetes / Endocrinology
Possible similar drugs: Lescol; Lescol XL

| General Information |

General Information

Lescol has been approved for a new indication--a treatment to decrease the progression of coronary atherosclerosis in patients with coronary heart disease undergoing treatment programs to lower lipoprotein cholesterol. Lescol was originally approved in 1994 for patients with primary hypercholesterolemia.

< back to top

Lescol Drug Information

The Lescol drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.